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Adiponectin levels are increased in patients with type I
diabetes especially in the presence of microangiopathy. Here
we determined the predictive value of serum adiponectin
levels and 8 adiponectin gene polymorphisms for mortality,
cardiovascular events and end-stage renal disease in type I
diabetic patients. This prospective, observational follow-up
study of type I diabetics consisted of 438 patients with overt
diabetic nephropathy that were compared to 440 type I
patients with normal albumin excretion. These two groups
were followed an average of 8 years and generally matched
for gender, age and duration of diabetes. Cox regression
analysis of 373 patients showed a covariate-adjusted hazard
ratio for all-cause mortality of 1.46 for a change of one
standard deviation in log10 of serum adiponectin. There was
no association with cardiovascular events; however, serum
adiponectin levels predicted end stage renal disease in a
covariate-adjusted analysis. Two of eight gene
polymorphisms, found in the 878 patients, were associated
with increased serum adiponectin levels but none of the
polymorphisms were associated with a renal or
cardiovascular outcome. These studies show that high serum
adiponectin levels predict mortality and progression to end
stage renal disease in type I diabetic patients.
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Proteinuric patients with type I diabetes have an increased
mortality compared to the general population, mainly
explained by end-stage renal disease (ESRD) and cardiovas-
cular disease (CVD).1
The adipocyte secretes a number of peptides labeled
adipocytokines or adipokines. The most abundantly secreted
adipokine is adiponectin, which is induced during adipocyte
differentiation. In experimental studies and in type II diabetic
patients, adiponectin has been shown to possess anti-
inflammatory, antiatherogenic, and cardioprotective proper-
ties.2 Furthermore, adiponectin has been suggested to
enhance insulin action.3,4
Recently, two cell surface receptors for adiponectin have
been identified. The two receptors are expressed in most
tissues, but liver and muscle showed by far the most
prominent expression.5 Receptor activation has been shown
to stimulate AMP-activated protein kinase and peroxisome
proliferator-activated receptor-g, fatty-acid oxidation, and
glucose uptake.5,6 These actions suggest a role of adiponectin
as an endogenous insulin sensitizer.3,4
Low concentrations of adiponectin have been associated
with obesity,7,8 type II diabetes,7,9 and coronary artery
disease.9–12 In addition, with respect to kidney disease in
type I diabetes, serum adiponectin levels are increased and
associated with microangiopathy.11,13–15 The levels of adipo-
nectin are influenced by genetic variations in the adiponectin
(ADIPOQ) gene.16 However, the relationship between con-
centrations of adiponectin and microangiopathy is not fully
understood, but we have previously shown that genetic
variations in the ADIPOQ gene are associated with the risk of
diabetic nephropathy.17 This prompted us to investigate
whether serum levels of adiponectin and eight polymorph-
isms in the ADIPOQ gene predict all-cause mortality, CVD
events, and ESRD in a well-characterized population of type I
diabetic patients with or without diabetic nephropathy.
Furthermore, we wanted to investigate whether associations
with genetic variants are driven through increased adipo-
nectin levels.
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RESULTS
Baseline characteristics
This was a prospective observational follow-up study with a
median follow-up time until end point or last visit of 8.1
(0.0–12.8) years. From Denmark, 952 patients were originally
included in the EURAGEDIC case–control study.18 In 52
patients no follow-up was possible and 22 individuals had at
least one unreported genotype due to technical reasons. The
remaining study population included two groups: 438 cases
with type I diabetes and diabetic nephropathy and 440
controls with type I diabetes for more than 15 years and
persistent normoalbuminuria. Baseline clinical and labora-
tory characteristics of the 878 patients are shown in Table 1.
Patients with nephropathy were younger, received more
antihypertensive treatment, had higher HbA1c, blood pres-
sure, serum creatinine and total cholesterol, but lower
concentrations of high-density lipoprotein cholesterol than
patients with normoalbuminuria (Po0.05). There was a
correlation between adiponectin and the following para-
meters: Age (r¼ 0.17), serum levels of creatinine (r¼ 0.41),
weight (r¼0.28), urinary albumin excretion rate (r¼ 0.29),
and high-density lipoprotein cholesterol (r¼ 0.27), and all
P-values were o0.001. On average, glomerular filtration rate
(GFR) was well preserved in patients with diabetic nephro-
pathy, but nevertheless, in type I diabetic patients serum
adiponectin was significantly higher in individuals with
diabetic nephropathy, as previously published.13 Further-
more, after adjustment for the presence of nephropathy,
patients carrying the minor allele in 11387 and the non-A-
allele in þ 2033 had significant elevated adiponectin
concentrations, P¼ 0.031 and 0.040. However, associations
disappeared after Bonferroni correction for multiple testing.
Allele and genotype frequencies for the eight variants in the
ADIPOQ gene were compatible with the Hardy–Weinberg
equilibrium. Allele frequencies for all polymorphisms are
shown in Table 2. Interestingly, the two polymorphisms
associated with increased adiponectin levels were also
nominally associated with diabetic nephropathy in the
case–control study: The A-allele in 11387 was associated
with diabetic nephropathy (A-allele frequency: 9.4 versus
6.6% in cases and controls, respectively, P¼ 0.014), as well as
þ 2033 (the non-A-allele frequency: 37.0 versus 41.3% in
cases and controls, respectively, P¼ 0.050).
Follow-up data
In 373 patients, circulating levels of adiponectin were
measured. Data were evaluated with adiponectin as a
continuous variable. During follow-up, 19 (10.9%) patients
with normoalbuminuria and 79 (39.9%) patients with
macroalbuminuria died. Cox regression analysis revealed an
increased risk for all-cause mortality with a hazard ratio
(HR) of 1.75 (1.47–2.10, Po0.001) for a change of one s.d.
(0.21) in log10 of serum adiponectin. Adiponectin remained
an independent predictor of all-cause mortality in the Cox
regression model (covariate-adjusted (sex, age, ±nephro-
pathy, systolic blood pressure, HbA1c, serum creatinine,
serum cholesterol, and antihypertensive treatment) HR 1.46
(1.07–2.00, P¼ 0.018)). This association was linear and the
interaction term between case–control group and adiponectin
level was significant (P¼ 0.037). However, no associations
were seen when analyzing cases and controls separately in a
multivariate Cox regression model (P¼ 0.428 and 0.093). In
addition, one s.d. increase of log10 of serum adiponectin was
associated with an increased risk of the combined end point
Table 1 | Baseline clinical and laboratory characteristics of the 878 patients divided according to nephropathy status
Nephropathy (N=438) Normoalbuminuria (N=440) P-value
Sex (men/women) 267/171 233/207 0.017
Age (years) 42.3±10.4 45.4±11.5 o0.001
Duration of diabetes (years) 28.4±8.8 27.7±10.1 0.29
BMI (kg/m2) 24.2±3.3 24.2±3.1 0.80
HbA1c (%) 9.4±1.5 8.4±1.1 o0.001
Antihypertensive treatment (%) 77.3 16.6 o0.001
sBP (mm Hg) 145±22 134±19 o0.001
dBP (mm Hg) 83±12 76±10 o0.001
UAER (mg per 24 h) 593 (3–14,545)a 7 (1–30) —
S-creatinine (mmol/l) 103 (52–706) 79 (53–134) o0.001
GFR (crEDTA, ml/min per 1.73 m2) 74±34 — —
eGFR (ml/min per 1.73 m2) 66±28 87±16 o0.001
S-cholesterol (mmol/l) 5.6±1.2 4.9±1.0 o0.001
S-HDL cholesterol (mmol/l) 1.5±0.6 1.6±0.5 0.002
S-triglycerides (mmol/l) 1.3 (0.3–9.9) 0.8 (0.3–5.4) o0.001
Smoking (%) 45.8 39.5 0.08
Retinopathy (0/SR/PR) 7/133/298 159/163/118 o0.001
Myocardial infarction (%) 4.5 1.8 0.03
Stroke (%) 7.0 1.6 o0.001
S-adiponectin (mg/l)b 24.2 (7.6–117.5) 17.3 (6.1–48.6) o0.001
BMI, body mass index; dBP, diastolic blood pressure; GFR, glomerular filtration rate; HDL, high-density lipoprotein; LDL, low-density lipoprotein; PR, proliferative retinopathy;
sBP, systolic blood pressure; SR, simplex retinopathy; UAER, urinary albumin excretion rate.
aSome patients with previously persistent macroalbuminuria receiving antihypertensive treatment had values o300 mg per 24 h at the time of investigation.
bN=198 patients with diabetic nephropathy and N=175 patients with normoalbuminuria. Data are expressed as N, means±s.d., medians (range).
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(fatal and non-fatal CVD events) (N¼ 107) in a univariate
proportional hazards model (HR 1.50 (1.26–1.78, Po0.001).
However, this association disappeared when adjusting for
confounding factors (P¼ 0.59). No further analyses were
performed regarding this end point.
Progression of renal disease. During follow-up, only one
patient with normoalbuminuria developed macroalbuminur-
ia and none progressed to ESRD. Nevertheless, 40 (23.2%)
patients with diabetic nephropathy reached ESRD (Table 3).
Progressors received more antihypertensive treatment, had
higher urinary albumin excretion rate, and serum adiponec-
tin concentrations, but lower GFR (Table 4). Cox regres-
sion analysis revealed an unadjusted HR for ESRD of 2.09
(1.59–2.75, Po0.001) for a change of one s.d. in log10 of
serum adiponectin; covariate-adjusted (sex, age, ±nephropathy,
systolic blood pressure, HbA1c, serum creatinine, serum
cholesterol, and antihypertensive treatment) HR of 1.45
(1.01–2.09, P¼ 0.047). This association was linear and the
interaction term for case–control group and serum adipo-
nectin was significant (P¼ 0.003). We then examined the risk
estimates in the group of patients with diabetic nephropathy
separately (N¼ 198). These patients were divided into two
groups according to the median level of serum adiponectin
(24.2 (7.6–117.5) mg/l). During follow-up, 12 patients (12%)
with adiponectin levels below the median and 28 patients
(30%) with levels above the median reached ESRD
(P¼ 0.001; Figure 1). Cox regression analysis revealed an
unadjusted HR for ESRD in patients with adiponectin levels
above the median of 3.44 (1.75–6.78, Po0.001); covariate-
adjusted (sex, age, systolic blood pressure, HbA1c, GFR,
serum cholesterol, and antihypertensive treatment) HR of
2.72 (1.27–5.84, P¼ 0.010). Similar results were found when
analyzing adiponectin as a continuous variable. In addition,
the result did not change when adjusting for high-density
lipoprotein cholesterol instead of total cholesterol. Further-
more, rate of decline in kidney function was explored in
Table 2 | Allele frequencies (%) of the 878 patients divided
according to nephropathy status
Polymorphism Allele
Nephropathy
(N=438)
Normoalbuminuria
(N=440) P-value
11422 G 9.5 9.0 0.81
(rs16861194) A 90.5 91.0
11387 G 90.6 93.4 0.014
(rs17300539) A 9.4 6.6
11373 C 76.8 73.8 0.33
(rs266729) G 23.2 26.2
10065 A 32.9 35.0 0.51
(rs182052) G 67.1 65.0
+45 (rs2241766) G 10.5 10.0 0.81
T 89.5 90.0
+276 G 68.6 72.5 0.22
(rs1501299) T 31.4 27.5
+1242 C 2.9 3.0 1.00
(rs17366743) T 97.1 97.0
+2033 A 37.0 41.3 0.050
AA 63.0 58.7
Table 3 | Clinical characteristics of 373 patients with
adiponectin measurements classified according to guidelines
of American clinical practice (K/DOQI)
eGFR
stage
Number of
patients (%)
UAER (mg per
24 h)
Progression to
ESRD (N (%))
S-adiponectin
(mg/l)a
Nephropathy (N=198)
I 22 532 (16–5145) 2 (5) 21.6 (7.7–54.6)
II 37 736 (35–8824) 8 (11) 20.4 (7.6–64.0)
III 30 1444 (46–14,545) 18 (31) 26.9 (8.9–111)
IV 9 1904 (43–6735) 11 (65) 33.9 (15.6–117.5)
V 2 1208 (452–4099) 1 (20) 56.4 (32.6–109.2)
Normoalbuminuria (N=176)
I 59 7 (1–30) 0 17.0 (8.8–37.8)
II 39 8 (1–30) 0 17.9 (6.1–45.2)
III 2 15 (7–21) 0 35.6 (12.1–48.6)
IV 0 — — —
V 0 — — —
ANOVA, analysis of variance; eGFR, estimated glomerular filtration rate; ESRD, end-
stage renal disease; UAER, urinary albumin excretion rate.
The different stages of renal insufficiency are based on eGFR calculated by the
modification of diet in renal disease method.
aA statistically significant difference in adiponectin concentration was seen in
patients with nephropathy (P=0.034 (ANOVA)). No association was seen in patients
with normoalbuminuria (P=0.67). Data are expressed as N, medians (range). The five
stages based on eGFR are as follows: IX90, II=60–89, III=30–59, IV=15–29, and Vo15.
Table 4 | Clinical characteristics of the198 patients with
adiponectin measurements and diabetic nephropathy
divided according to ESRD status
Progressor
(N=40)
Non-progressor
(N=158) P-value
Sex (men/women) 27/13 92/66 0.09
Age (years) 41.2±8.6 40.8±9.8 0.81
BMI (kg/m2) 24.4±4.5 23.9±2.8 0.39
HbA1c (%) 10.0±1.5 9.4±1.5 0.019
Antihypertensive
treatment (%)
91.3 66.4 0.001
sBP (mm Hg) 162±23 148±21 o0.001
dBP (mm Hg) 93±12 84±12 o0.001
UAER (mg per 24 h) 2191 (35–14545) 644 (16–8824) o0.001
GFR (ml/min per 1.73 m2) 44±26 83±30 o0.001
S-adiponectin (mg/l) 29.0 (7.7–117.5) 22.5 (7.6–109.2) 0.012
BMI, body mass index; dBP, diastolic blood pressure; ESRD, end-stage renal disease;
GFR, glomerular filtration rate; sBP, systolic blood pressure; UAER, urinary albumin
excretion rate.
Data are expressed as N, means±s.d., medians (range).
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Figure 1 | Kaplan–Meier curves of end-stage renal disease
(ESRD) in 198 type I diabetic patients with diabetic
nephropathy (P¼ 0.010). Grey line, serum adiponectin levels
below the median; black line, serum adiponectin levels above the
median.
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patients with diabetic nephropathy using annually measured
GFR (N¼ 186 patients). Mean rate of decline in GFR differed
significantly according to adiponectin levels: low levels 3.6
(3.8) ml/min per 1.73 m2 per year and high levels 5.0 ml/min
per 1.73 m2 per year, P¼ 0.045. This effect persisted
after correction for sex and age; however, this association
disappeared when adjusting for well-known progression
promoters (P¼ 0.36).
A prospective follow-up analysis was performed to investi-
gate the common polymorphisms in the ADIPOQ gene in
relation to development of ESRD, CVD events, and mortality
in type I diabetic patients with and without diabetic
nephropathy (N¼ 878). A total of 90 (10.3%) patients
progressed to ESRD, 211 (24.0%) patients had a fatal or
non-fatal CVD event and 176 (20.0%) patients died during
follow-up. However, none of the polymorphisms predicted
renal/cardiovascular outcome.
DISCUSSION
The current case–control study with 8.1 years of follow-up
demonstrated that high levels of serum adiponectin predict
all-cause mortality and progression to ESRD in patients with
type I diabetes. This effect persisted after adjustment for sex,
age, established progression promoters, and antihypertensive
treatment. Furthermore, two polymorphisms in the ADIPOQ
gene were associated with serum adiponectin levels, but no
associations were seen when adjusting for multiple testing.
None of the eight polymorphisms investigated were asso-
ciated with renal/cardiovascular outcome.
Adiponectin appears to play a major role in fatty acid and
glucose metabolism through a change in insulin sensitivity by
stimulating peroxisome proliferator-activated receptor-g and
the AMP-activated protein kinase.2 In previous studies,
insulin resistance has been linked to microalbuminuria in
type I diabetes,19 but as insulin resistance was not evaluated
in the current population of type I diabetic patients we
cannot evaluate the relationship among the levels of
adiponectin, insulin sensitivity, and diabetic nephropathy.
Nevertheless, it is possible that the elevation of adiponectin is
unrelated to the insulin sensitivity. Apart from being an
endogenous insulin sensitizer, adiponectin exerts a plethora
of anti-inflammatory, antiatherogenic, and cardioprotective
properties.2 Adiponectin modulates endothelial function
by inhibition of the deleterious effects of tumor necrosis
factor-a10,20,21 and increases the activity of endothelial nitric
oxide synthase.22 Endothelial nitric oxide synthase is an
enzyme responsible for NO synthesis leading to increased
NO levels. Furthermore, adiponectin reduces expression of
the vascular cell adhesion molecule-1, E-selectin, and
intracellular adhesion molecule-1.10
In previous studies, low concentrations of adiponectin
have been associated with obesity,7,8 type II diabetes,7,9 and
coronary artery disease.9–12 In addition, with respect to
kidney disease in type I diabetes, the present study
demonstrated that levels of adiponectin are increased in type
I diabetic patients with diabetic nephropathy and predict
development of ESRD. This is in accordance with previous
studies11,13–15 in which high concentrations of adiponectin
were demonstrated in type I diabetic patients with diabetic
nephropathy. Furthermore, a recent study identified elevated
levels of adiponectin as a novel predictor for chronic kidney
disease progression in male non-diabetic patients.23
An essential question to be answered is why coexisting
type I diabetes and diabetic kidney disease is associated with
increased concentrations of adiponectin. Clearance of
adiponectin from the circulation is mainly renal dependent
and deteriorated kidney function increases levels of adipo-
nectin in both type I and II diabetes.13,14,24 Consequently,
differences in kidney function need to be taken into
consideration when comparing different study groups. In
addition, ACE inhibitors have been shown to increase serum
adiponectin in non-diabetic patients with essential hyperten-
sion.25 In the current study, treatment with ACE inhibitors13
were not associated with serum adiponectin and all analyses
were adjusted for antihypertensive treatments and serum
creatinine or actual GFR measured with a clearance tech-
nique. Thus, mechanisms other than kidney function must
be responsible for the elevated levels of serum adiponectin
and progression to ESRD in type I diabetes.
The adiponectin protein has three distinct domains
corresponding to a signal sequence with a variable region, a
collagenous triple helix, and a globular head domain.2
Functional studies have shown that four lysine residues in
the collagenous domain of adiponectin can be both hydroxy-
lated and glycosylated.26 These post-translational modifica-
tions lead to a changed three-dimensional structure and
might be a consequence of hyperglycemia, oxidative stress,
and chronic low-grade inflammation that are a part of type I
diabetes and diabetic nephropathy. This hypothesis is
supported by recent data. Adiponectin multimer composi-
tion is affected by physiological factors, and most notably,
even a relatively short period of high plasma glucose leads to
an increase in the production of high-molecular-weight
polymers of adiponectin.27 Kollerits et al.23 suggest that the
post-translational modifications affect receptor affinity and
result in adiponectin resistance. For this reason, it is
conceivable that the increased levels of adiponectin is a
counter-regulatory response to metabolic derangements in
type I diabetes and renal failure.28 Whether this phenomenon
is present in chronic hyperglycemia in type I diabetic patients
with diabetic nephropathy is unknown.
In the present study, we have determined total adiponectin
levels without differentiating among the various isoforms.
However, recent data indicate that it is the plasma fraction of
high-molecular-weight polymers rather than the total con-
centration of adiponectin that is associated with insulin
sensitivity in db/db mice as well as in type II diabetic patients
treated with thiazolidinedione.29 On the other hand, in
patients with polycystic ovary syndrome treated with
thiazolidinedione, total adiponectin levels yielded stronger
correlations with changes in insulin sensitivity than the high-
molecular adiponectin isoform as determined with fast
652 Kidney International (2008) 74, 649–654
o r i g i n a l a r t i c l e A Jorsal et al.: Adiponectin predicts mortality and ESRD
protein liquid chromatography.30 Future studies estimating
different isoforms of adiponectin are needed to elucidate the
paradoxically elevated adiponectin levels in type I diabetes as
well as their exact role in relation to metabolism and
development of late diabetic complications.
It has been suggested in several studies that genetic factors
may influence the risk of developing micro- and macro-
vascular complications in type I diabetes.31,32 We have
previously shown that genetic variations in the ADIPOQ
gene are associated with the risk of diabetic nephropathy.17
The present study demonstrated that patients carrying the
minor allele in 11387 and the non-A-allele in þ 2033 had
significant elevated serum adiponectin levels. This finding is
in accordance with a large study in non-diabetic individuals
(N¼ 1727).16 Thus, data confirm that the association with
diabetic nephropathy is likely to be due to the effect of the
polymorphisms on adiponectin levels. However, our study
did not show any relationship between genetic variants in the
ADIPOQ gene and the development of ESRD, CVD events, or
mortality. This might be a matter of lack of statistical power
to detect an impact of the relatively infrequent genetic
variants.
In conclusion, in this well-characterized population of
type I diabetic patients we demonstrated that adiponectin
predicts all-cause mortality and ESRD. Future studies are
needed to elucidate the exact roles of different isoforms of
adiponectin and insulin resistance in relation to metabolism,
development, and progression of late-diabetic complications.
MATERIALS AND METHODS
Patients
Since 1993, all adult Danish Caucasian patients with type I diabetes
and diabetic nephropathy attending the outpatient clinic at Steno
Diabetes Center have been invited to participate in a study of genetic
risk factors for the development of diabetic micro- and macro-
vascular complications. Of these, 73% accepted. Type I diabetes was
considered present if the age at onset of diabetes wasp35 years and
time to definite insulin therapy p1 year. Established diabetic
nephropathy (cases) was defined by persistent albuminuria
(4300 mg per 24 h) in two out of three consecutive measurements
in sterile urines, presence of retinopathy, and absence of other
kidney or urinary tract disease.33 In four cases without retinopathy,
the diagnosis of diabetic glomerulopathy was verified by a kidney
biopsy. Absence of diabetic nephropathy (controls) was defined as
persistent normoalbuminuria (o30 mg per 24 h) after at least 15
years of type I diabetes in patients not treated with ACE inhibitors
or angiotensin II receptor blockers. In total, 76% of patients
approached as controls. No patients were treated with thiazoli-
dinedione.
Baseline clinical and laboratory investigations
All patients had blood samples and phenotypic characteristics
collected as part of the EURAGEDIC project.18 Blood pressure was
measured twice in the resting state. From venous samples, plasma
lipid levels were determined by standard methods. HbA1c was
determined by standard high-performance liquid chromatography
techniques with normal values in the range from 4.1 to 6.4%.
Urinary albumin excretion rate was measured in 24-h urine
collections by an enzyme immunoassay. Serum creatinine concen-
tration was determined by a modified Jaffe’s method. GFR was
measured annually in patients with diabetic nephropathy after a
single injection of 3.7 MBq 51Cr-EDTA by determination of
radioactivity in venous blood samples taken 180, 200, 220, and
240 min after injection.34 Linear regression analysis of the GFR
determinations in each individual was used to estimate the rate of
decline in kidney function. In patients with normoalbuminuria, the
GFR was estimated by the modification of diet in renal disease
equation.35 ESRD was defined as kidney transplantation or dialysis.
Diabetic retinopathy was assessed by fundus photography after
pupillary dilatation and graded nil, simplex, and proliferative
retinopathy. On the basis of standardized questionnaires, current
smokers of one or more cigarettes/cigars/pipes per day were
classified as smokers and all others as non-smokers. Major CVD
events were diagnosed as stroke, myocardial infarction, coronary
artery bypass graft, and/or percutanous coronary intervention.
The genotyping was performed as part of the EURAGEDIC study
using standard methods as recently described.17 The following
eight polymorphisms in the ADIPOQ gene––listed according to the
first position of the translation starting point ATG––were analyzed:
11422 (rs16861194), 11387 (rs17300539), 11373 (rs266729),
10065 (rs182052), þ 45 (rs2241766), þ 276 (IVS2G62T, rs1501299),
þ 1242 (Y111H, rs17366743), and þ 2033.
Serum adiponectin was measured in a subgroup of 373 patients
(175 patients with normoalbuminuria and 198 patients with
macroalbuminuria). These patients did not differ from the whole
study population with respect to sex, age, and duration of diabetes.
Serum adiponectin was determined by an in-house time-resolved
immunofluorometric assay based on commercial reagents (from
R&D Systems, Abingdon, UK) as recently described.13
Follow-up
In a prospective observational study design, the patients were
followed until an end point was reached, to the last visit at Steno
Diabetes Center or until the 1st of September 2006. The end points
were ESRD, major cardiovascular events, cardiovascular mortality,
and all-cause mortality.
All patients were traced through the National Register during
autumn 2006. If a patient died before the 1st of September 2006, the
date of death was recorded and information on cause of death was
obtained from the death certificate. Two observers reviewed all death
certificates independently and the primary cause of death was
recorded. Additional available information from necropsy reports
was included. All deaths were classified as cardiovascular deaths
unless an unequivocal non-cardiovascular cause was established.36
Information about date of ESRD and non-fatal CVD events was
obtained from patient records or discharge letters from other
hospitals.
The study was performed in accordance with the Helsinki
Declaration, the local ethics committee approved the study and all
patients gave their informed consent.
Statistical analysis
Normally distributed variables are given as means±s.d., whereas
non-normally distributed variables were log10 transformed before
analysis and are given as medians (range). Comparisons between
groups were performed by an unpaired Student’s t-test, analysis of
variance, or linear regression as appropriate. The w2 test was used to
compare non-continuous variables. A two-tailed P-value of 0.05 or
less was considered statistically significant.
Kidney International (2008) 74, 649–654 653
A Jorsal et al.: Adiponectin predicts mortality and ESRD o r i g i n a l a r t i c l e
All time-to-end point variables were analyzed using a log-rank
test and displayed in Kaplan–Meier plots. Cox regression models
were used to estimate the unadjusted and adjusted HRs with 95%
confidence interval. The models were tested for a nonlinear
relationship with serum adiponectin by evaluation of the signifi-
cance of adding a quadratic term. All patients were analyzed
together, but as the study was initially a case–control study we added
an interaction term for case–control group and adiponectin level, if
significant we evaluated cases and controls separately.
All calculations were performed using a commercially available
program (SPSS for Windows, version 14.0, Chicago, IL, USA).
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